Company Overview - Hangzhou Bangshun Pharmaceutical Co., Ltd. is a biotechnology company focused on oncology and autoimmune diseases, with a pipeline that includes one NDA-stage candidate (Bezeixinib), one registration clinical-stage candidate (CX1440), and five preclinical candidates (CX03, CX12, CX13, CX15, and CX16) [2] - Bezeixinib is expected to be one of the first three domestically approved JAK inhibitors for treating myelofibrosis (MF) in China, with clinical trials ongoing in MF, polycythemia vera (PV), and essential thrombocythemia (ET) [2] - CX1440 is a third-phase clinical BTK inhibitor, ranked among the top three globally for treating immune thrombocytopenia (ITP) and among the top two for chronic urticaria (CU) and autoimmune hemolytic anemia (AIHA) [3] Financial Performance - The company reported revenues of RMB 943,000 for the fiscal year 2024 and the nine months ending September 30, 2024, with no revenue reported for the nine months ending September 30, 2025 [4][6] - Losses for the fiscal year 2024 were approximately RMB 88.44 million, with losses of RMB 66.34 million and RMB 179.33 million for the nine months ending September 30, 2024, and 2025, respectively [5][6] Market Overview - The global MPN drug market is projected to grow from USD 6.6 billion in 2020 to USD 8.3 billion in 2024, with a CAGR of 6.0%, and is expected to reach USD 12.7 billion by 2030 [7] - The Chinese MPN drug market is expected to expand from USD 700 million in 2020 to USD 900 million in 2024, with a CAGR of 6.4%, and is projected to reach USD 1.6 billion by 2030 [7] - The market for ITP drugs in China is anticipated to grow from approximately USD 700 million in 2024 to USD 3.6 billion by 2035, with a CAGR of 15.0% [3] - The autoimmune disease drug market in China is expected to grow from USD 2.5 billion in 2020 to USD 4.6 billion in 2024, with a CAGR of 15.9%, and is projected to reach USD 18.4 billion by 2030 [18]
新股消息 | 邦顺制药递表港交所 专注于肿瘤及自身免疫性疾病领域
智通财经网·2026-01-22 11:40